pemigatinib (Pemazyre)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 13.5 mg orally once daily for 14 consecutive days followed by 7 days off i 21-day cycles
  • continue treatment until disease progression or unacceptable toxicity
  • Swallow tablet whole, with or without food

Tabs: 4.5 mg, 9 mg, & 13.5 mg

Monitor

Adverse effects

Drug interactions

  • strong or moderate cyp3A inducers or inhibitors

Mechanism of action

More general terms

References

  1. Pubchem: 86705695
  2. HIGHLIGHTS OF PRESCRIBING INFORMATION PEMAZYRETM (pemigatinib) tablets, for oral use https://www.pemazyre.com/pdf/prescribing-information.pdf

Database